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▼The combination of Drosophila genetics with DNA tech-
nology has enabled rapid progress in many areas of mod-
ern biology. An invaluable resource for Drosophila work-
ers is stocks carrying chromosomes in which a region is
deleted. Traditionally, the endpoints of deletions on de-
ficiency chromosomes are mapped by cytology from the
banding pattern of larval polytene chromosomes. One ex-
ample of the use of deficiency stocks is in mapping mu-
tants to a chromosomal region. If the corresponding wild-
type gene is missing in the deficiency chromosome, then
the heterozygote of the mutant with the deficiency will be
phenotypically mutant and the gene is ‘uncovered’ by the
deficiency.
Many Drosophila genes are now being identified for
which mutants do not exist, for example because they are
homologous to genes from other organisms, or from anal-
ysis of the genomic DNA sequence. If these genes can be
mapped accurately, then existing mutants might be identi-
fied, or limits set for mutageneses to create mutants. Cloned
DNA can be mapped with respect to deficiencies (deficiency
mapping) by hybridization to polytene chromosomes from
larvae that are heterozygous for wild-type and deficiency
chromosomes. As homologues remain paired in polytene
chromosomes, spreads that are made from such heterozy-
gotes reveal the position of the deficiency as a loop in which
the wild-type chromosome has no corresponding homolo-
gous region on the deficiency chromosome. Hybridization
of a cloned gene to such spreads can determine if the gene is
inside (hybridization to the loop) or outside (hybridization
to the paired regions) the deletion.
We describe here an alternative strategy for deficiency
mapping using polymerase chain reaction (PCR) on DNA
from single embryos of balanced deficiency stocks. One
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quarter of the embryos are homozygous for the deficiency
chromosome, one quarter are homozygous for the balancer
and half are heterozygous for the deficiency and balancer
chromosomes. Balancer chromosomes carry lethal or ster-
ile mutations, so only the heterozygous embryos develop
into fertile adults, allowing propagation of the balanced
stock. However, owing to maternal contribution, the ho-
mozygous deficiency and homozygous balancer embryos
will go through at least the early stages of embryonic de-
velopment. Provided the balancer chromosome carries a
molecular marker of some description, then using PCR and
primers that are specific for the molecular marker, homozy-
gous deficiency embryos can be identified by their failure
to amplify the balancer-specific fragment. To avoid false
negative results, for example because of loss of the embryo
or failure to produce DNA during processing the embryo,
a second pair of primers for a control sequence on another
chromosome should be used. Homozygous deficiency em-
bryos can then be assessed with primers that are specific for
the gene being mapped.
Protocol
Balanced deficiency stocks were allowed to lay on grape-
juice collection trays. Embryos were collected either
in the morning after an overnight laying period, or
after a 4 h laying period during the day. They were
then allowed to develop for several more hours before
extraction.
DNA that was suitable for PCR was prepared as described
previously (Ref. 1, 2). A single embryo was transferred
to a 0.5 ml tube and crushed using a micro-pipette
tip in 10 µl of extraction buffer (10 mM Tris pH 8.2,
1 mM EDTA, 25 mM NaCl and 200 µg ml−1 proteinase
K (Sigma) that was freshly diluted from a frozen 20 mg
ml−1 stock). By checking for debris using a dissecting
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FIGURE 1. Deficiency mapping by single-embryo polymerase chain reaction (PCR). Lane 1, molecular weight marker; lanes 2–4, Df(3R)ChaM5/Balancer
embryo amplified in three separate reactions with primers for the control gene, gene being mapped and balancer-specific marker, respectively; lanes 5–8,
four single Df(3R)ChaM5/Balancer embryos amplified simultaneously with all three sets of primers; lanes 9–12, four single Df(3R)fruW24/Balancer embryos
amplified simultaneously with all three sets of primers. Asterisks indicate lanes from homozygous deficiency embryos.
microscope it was possible to discard samples in which
the embryo had been lost in transfer, or in which the
embryo had become stuck inside the pipette tip.
The samples were incubated at 37◦C for 30 min and then
at 95◦C for 5 min. Typically, 1 µl of this preparation
was used in a 10–50 µl PCR reaction with 20 mM
Tris-HCl pH 8.4 (at 25◦C), 5 mM KCl, 0.1% W1 de-
tergent (Gibco BRL), 2 mM MgCl2, 0.25 mM dNTPs
(Pharmacia Biotech) and 1 U (5 U µl−1) Taq poly-
merase (MBI Fermentas). As optimal PCR conditions
vary for different sets of primers, preparations were as-
sessed first in separate reactions that were optimized
for each pair of oligonucleotide primers (Genosys). To
use all three pairs of primers in a single reaction, it
was necessary to adjust the primer concentrations or
other PCR parameters to avoid generating non-specific
fragments.
The following oligonucleotides (Genosys) were used: 5′-
CGATGACACTATCGCAGTTACATCC-3′ and 5′-CTGGTTTTAAGT
TGGAATTTAGAAAGAAC-3′ for the X chromosome control
gene (1119 bp product); 5′-ATGCAGCAGCTGCTTCAGGG-3′
and 5′-CAATCTGTTCGTCGGACAGC-3′ for the gene being
mapped (886 bp product); 5′-CGACTGATCCACCCAGTCCC-
3′ and 5′-GCGATGTCGGTTTCCGCGAG-3′ for the balancer-
specifc P-lacZ gene (739 bp product).
The PCR reactions contained 2 µl of embryo DNA in a total
of 40 µl with 20 ng of each lacZ primer, 100 ng of each
control primer and 40 ng of each primer for the gene
being mapped. After denaturation at 95◦C for 3 min,
16 cycles were made with denaturation for 0.5 min at
95◦C, annealing for 1min starting at 55◦Cbut dropping
by 0.25◦C per cycle, and extension for 2.5 min at 72◦C.
A further 24 cycles were then made with a constant
annealing temperature of 51◦C.
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The PCR products were analyzed by electrophoresis at 5 V
cm−1 for 90min on an 8 cm long, 1.5% agarose Nusieve
GTG (Flowgen) gel in TBE buffer (90 mM Tris-borate
pH 8.3, 2 mM EDTA) containing 0.5 µg ml−1 ethidium
bromide. DNAwas detected by illumination at 302 nm.
We have isolated a gene in a yeast two-hybrid screen
and used this technique to map it with respect to sev-
eral deficiencies including Df(3R)fruW24 (91A1;91D2–3)
andDf(3R)ChaM5 (91B3;91D1). The third chromosome bal-
ancer present in the deficiency stocks carried a P-lacZ trans-
gene and primers from the E. coli β-galactosidase gene were
used to identify balancer embryos. Primers for a gene on
the X chromosome were used as a control. DNA from some
embryos of both stocks amplified all three fragments, in-
dicating that these embryos were either heterozygotes or
homozygous for the balancer chromosome (Figure 1). Em-
bryos whose DNA generated the control fragment but not
the balancer-specific fragment must be homozygous for
the deficiency (shown with an asterisk in Figure 1). The
gene of interest could be amplified using DNA prepara-
tions from embryos of this class from Df(3R)ChaM5 but not
from Df(3R)fruW24. This shows that the gene of interest is
present on the Df(3R)ChaM5 chromosome but absent from
the Df(3R)fruW24 chromosome and must map to either re-
gion 91A1 to 91B3, or region 91D1 to 91D2–3.
We used a P-lacZ transgene as a marker for the balancer
chromosome, but any other molecular marker could be
used. The procedure identifies embryos that are homozy-
gous for the non-balancer chromosome and so could, for
example, be used to prepare DNA from homozygous lethal
mutants for amplification and DNA sequencing of the mu-
tant gene. There are some advantages in using PCR rather
than in situ hybridization. It can be difficult to produce a
strong hybridization signal if only a small probe is available
and some regions, such as the bases of the chromosome
arms, have poor cytology. PCR is not affected by these fac-
tors and is more likely to be in everyday use in the labora-
tory than in situ hybridization to polytene chromosomes.
As this technique generates a ‘yes or no’ answer, it is easier
to interpret than experiments aimed at distinguishing be-
tween two and one copies of a sequence in wild-type versus
deficiency stocks by DNA blotting (Ref. 3).
One problem that many Drosophila workers will have
experienced in using overlapping deficiencies characterized
by different groups is inconsistencies or differences in the
descriptions of deletion endpoints. This procedure can be
used to resolve these differences and produce a consistent
map. The technique has high resolution; for example, we
have mapped a gene as being deleted from only one of two
cytologically identical deficiencies.
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Products Used
proteinase K: proteinase K from Sigma
proteinase K: proteinase K from Boehringer
Mannheim
proteinase K: proteinase K from QIAGEN GmbH
Proteinase K: Proteinase K from PE Applied Biosys-
tems
dNTP: dNTP from Promega Corporation
dNTP: dNTP from PE Applied Biosystems
dNTP: dNTP from Pharmacia
dNTP: dNTP from Promega Corporation
dNTP: dNTP from Boehringer Mannheim
Taq DNA polymerase: Taq DNA polymerase from
PE Applied Biosystems
Taq DNA polymerase: Taq DNA polymerase from
Life Technologies (Gibco BRL)
Taq DNA polymerase: Taq DNA polymerase from
Life Technologies (Gibco BRL)
Taq DNA polymerase: Taq DNA polymerase from
Promega Corporation
Taq polymerase: Taq polymerase from Boehringer
Mannheim
Taq polymerase: Taq polymerase from Pharmacia
Taq polymerase: Taq polymerase from Bioline
Taq polymerase: Taq polymerase from Advanced
Biotechnologies
Taq polymerase: Taq polymerase from Boehringer
Mannheim
Taq polymerase: Taq polymerase from Bioline
Primers: Primers fromOswel Research Products Ltd
Primers: Primers fromOswel Research Products Ltd
NuSieve: NuSieve from FMC BioProducts
NuSieve: NuSieve from FMC BioProducts
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